摘要 |
This invention provides for the use of compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond in treating a subject suffering from cystic fibrosis, reducing or delaying the mortality of a subject suffering from cystic fibrosis or ameliorating symptoms associated with cystic fibrosis. |
申请人 |
MORRIA BIOPHARMACEUTICALS;YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM;THE TRUSTEES OF COLUMBIA UNIVERSITY;YEDGAR, SAUL;PRINCE, ALICE;YUVAL, COHEN |
发明人 |
YEDGAR, SAUL;PRINCE, ALICE;YUVAL, COHEN |